Brain Cancer

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.

When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH-wildtype glioblastoma.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

18F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly diagnosed glioblastoma.

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.

Survival improved in patients with recurrent grade 3 IDH-mutant astrocytoma who were treated with eflornithine and lomustine.

From the deaths of actor Paul Teal and Chicago Bulls player Bob Love to a contestant on “Jeopardy!” revealing his colon cancer diagnosis, here’s what’s happening in the oncology space this week.

Patients with glioblastoma experienced tumor control after complete in-situ vaccination and anti-PD-1 immunotherapy, researchers have reported.

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.

A colleague wrote about a dedicated oncology nurse who excels in patient care, demonstrates exceptional clinical skills and consistently goes above and beyond to improve patient outcomes.

A phase 2 clinical trial of a new brain cancer treatment is underway.

The FDA has accepted a new drug application for the glioma-imaging agent Pixclara, with a decision expected next year.

In some with grade 3 brain cancer, adding PCV chemotherapy regimen to radiation showed better survival outcomes than another type of chemotherapy, but safety should be considered.

While being a caregiver to my youngest daughter with brain cancer, I felt emotional turmoil while being away from my firstborn daughter.

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly diagnosed high-grade glioma.

Two months after giving birth to my daughter, I noticed something was unusual, which led to my diagnosis of anaplastic oligodendroglioma.

The Hall of Famer has died from brain cancer at the age of 58, the NBA has announced.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

When my daughter couldn't express her words while she received treatment for brain cancer, her eyes told me everything I needed to know.

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.

The novel glioblastoma treatment, APTN-101, had its new drug application accepted by the FDA.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations.

For patients with glioblastoma, collecting information about their disease and treatment options is important before providing informed consent.

The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery.